

Cod. PR. 2023

NEW!

Candioli
urology line



CystoCure

*Natural control of bacterial cystitis
and LUTD in cats and dogs*

31000011

**Candioli**
PHARMA

Urinary infections

Are these common diseases?

- Urinary infections are **very frequent in dogs** (American studies reports a 14% incidence in the entire canine population) with a prevalence in females. Such diseases record a lower incidence in cats (1-3%), with a preference for subjects aged over 10 years⁷.
- **Asymptomatic** or paucisymptomatic infections are **common**, especially in subjects presenting *diabetes mellitus* or *hyperadrenocorticism*, and in those under *corticosteroid therapy*⁷.
- **Recurrent infections and relapses** characterised by an apparent clinical clearance without concurrent microbiological healing are **very frequent**.

How do they develop?

- Pathogens most frequently isolated from urine culture are **E. coli (37-67%)**, **Proteus**, **Klebsiella** and **Pseudomonas**.
- **Bacteria adhere** to the epithelial lining by means of *fimbriae*. These are protei molecules (there are two types in E. coli: type I and type P) that bind glycosphingolipid receptors present on the epithelial surface.

What are the symptoms?

	LOWER URINARY TRACT	UPPER URINARY TRACT
Clinical signs	Dysuria, Strangury, Pollakiuria, Haematuria	Uraemia, Anorexia, Depression, Fever, Polyuria, Polydipsia
Physical examination	Possible pain on palpation of the bladder	Fever, Depression, Renal tenderness
Haematology	Normal	Leukocytosis, BUN, Creatinine
Urinalysis	Pyuria, Haematuria, Proteinuria, Bacteriuria (urine culture)	< specific gravity Pyuria, Haematuria, Proteinuria, Urine culture
Imaging diagnostics	No significant findings	Descending urography, ultrasound scan





CystoCure

Product Composition

Vaccinium macrocarpon (cranberry)

stand. titred extract with 10% polyphenols

- Contains natural tannins called **proanthocyanidine (PACs)** that inhibit adherence of Type P fimbriated *E. coli*^{8,12,16,22}.



- This inhibition entails a structural modification in protein molecules of fimbriae with a subsequent reduction in their adhesive strength to epithelial cell surface^{3,4,13}.
- The adhesive capacity of Type A PACs contained in *Vaccinium macrocarpon* is 200-fold that of Type B PACs contained in grapes, apples or green tea, which are completely inactive^{11,12,15,16}.
- **Fructose** inhibits the adhesion of Type I fimbriated *E. coli*^{3,5,9,11}.

Bioflavonoids

stand. titred extract with 40% hesperidine

- Group of glucosidic molecules extracted from the epicarp of citrus fruits and other vegetables. Hesperidine is one of the most representative of these




- They possess powerful antioxidant properties and, therefore, act as protective agents for the cellular integrity of the uroepithelium^{4,23}
 - They inhibit lipoperoxidation of cell membranes
 - They activate other important endogenous antioxidant systems: catalases, GSH, SOD
 - They neutralise the action of free radicals
- They reduce the action of chemical mediators of inflammation (i.e. chemokines, xantine-oxidase)¹⁸



CystoCure

For its anti-adhesivizing properties, it is specifically recommended for both acute and chronic BACTERIAL CYSTITIS and LUTD*, even combined with antibiotics and antispastic and antiinflammatory agents



Pathogenesis of urinary tract infections



CystoCure targets this region by modifying the adhesive strength of fimbriae to epithelial cell surface

CystoCure is recommended for the PREVENTION of:

recurrences

infections associated with urolithiasis

urethral caps and bacterial cystitis in cats

either alone or associated with special diets.

* (Lower Urinary Tract Disease)

CystoCure - SPC

1. Composition

Orange bioflavonoids (titrated at 40% in Hesperidin), Vaccinium macrocarpon dry extract (titrated at 10% in Polyphenols).

Excipients tablets: Microcrystalline cellulose, Brewer's yeast, Dicalcium phosphate (Ca 26% - P 18%), Magnesium stearate, Silicon dioxide.

Excipients powder: Maltodextrin, Silicon dioxide

2. Product description

Helps in improving urinary tract conditions. It is suited to complement treatment during urinary tract infections (UTI), in case of urolithiasis and idiopathic cystitis (LUTD), both during acute stages in association to specific therapies, and in recurrent or relapsing stages, alone or in association with specific diets.

3. Instructions for use

Administer directly into the mouth or mix with feed according to the following daily dosages:

Acute stages of urinary disorders

Powder: 2 scoops (1 g) per 10 kg of body weight twice a day

Tablets: 1 tablet per 20 kg of body weight twice a day

Recurrent or relapsing stages

Powder: 2 scoops (1 g) per 10 kg of body weight once a day

Tablets: 1 tablet per 20 kg of body weight once a day

In case of dry diet, moisten the feed to allow a good stickiness of the powder and its complete intake.

Treatment should last 15 to 30 days. Cycles can be repeated several times, following your Veterinarian advice.

CystoCure could be administered alone, or in association to usual therapies and specific diets, following your Veterinarian advice.

4. Packaging

Box containing 30 tablets - each tablet is 1g

Jar containing 30g of powder with scoop

Bibliography

- Bailey DT, Dalton C, Joseph Daugherty F, Tempesta MS. Can a concentrated cranberry extract prevent recurrent urinary tract infections in women? A pilot study. *Phytomedicine*. 2007 Apr;14(4):237-41
- Bononi M, Tateo F. Stabilization of cranberry anthocyanins in nutraceutical capsules. *Int J Food Sci Nutr*. 2007 Mar;58(2):142-9
- Di Martino P, Agniel R, David K, Templer C, Gaillard JL, Demys P, Botto H. Reduction of *Escherichia coli* adherence to uroepithelial bladder cells after consumption of cranberry juice: a double-blind randomized placebo-controlled cross-over trial. *World J Urol*. 2006 Feb;24(1):21-7
- Oreikorn K. Complementary and alternative medicine in urology. *British Journal of Urology*. 2005;96:117-71 184
- Eydelnant IA, Tufenkji N. Cranberry derived proanthocyanidins reduce bacterial adhesion to selected biomaterials. *Langmuir*. 2008 Sep 16;24(18):10273-81
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CY, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. *J Urol*. 2005 Aug;174(2):590-4
- Gunn-Moore D. Affezioni delle basse vie urinarie del gatto (FLUTO). *Atti del 55° Congresso Nazionale SQVAC, Milano 2007*, pp 146-75
- Gupta K, Chou MY, Howell A, Wobbe C, Grady R, Stapleton AE. Cranberry products inhibit adherence of p-fimbriated *Escherichia coli* to primary cultured bladder and vaginal epithelial cells. *J Urol*. 2007 Jun;177(6):2357-60
- Heinonen M. Antioxidant activity and antimicrobial effect of berry phenolics - a Finnish perspective. *Mol Nutr and Food Res*. 2007;51(6):684-91
- Hess MJ, Hess PE, Sullivan MR, Yalla SV. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. *Spinal Cord*. 2008 Sep;46(9):622-6
- Howell AB. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. *Mol Nutr Food Res*. 2007 Jun;51(6):732-7
- Howell AB, Reed JO, Krueger CG, Winterbottom R, Cunningham DG, Leathy M. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. *Phytochemistry*. 2005 Sep;66(18):2281-91
- Jepson R, Craig J. Cranberry for preventing urinary tract infections. *Cochrane Database Syst Rev*. 2008 Jan 23;(1):CD001321
- Johnson JR, Stell AL, Delavari P, Murray AC, Kuskowski M, Gastra W. Phylogenetic and pathotypic similarities between *Escherichia coli* isolates from urinary tract infections in dogs and extraintestinal infections in humans. *J Infect Dis*. 2001;183:897-906
- Lavigne JP, Bourg G, Botto H, Sotto A. Cranberry (*Vaccinium macrocarpon*) and urinary tract infections: study model and review of literature. *Pathol Biol (Paris)*. 2007 Nov;55(8-9):460-4
- Liu Y, Black MA, Caron L, Camesano TA. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of *E. coli*. *Biotechnol Bioeng*. 2006 Feb 5;92(2):297-305
- Nowack R. Cranberry juice: a well-characterized folk-remedy against bacterial urinary tract infection. *Wien Med Wochenschr*. 2007;157(13-14):325-30
- Park HH, et al. Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. *Arch Pharm Res*. 2008 Oct;31(10):1303-11
- Qiu X, Wu VCH. Evaluation of *Escherichia coli* 0157:H7, *Listeria monocytogenes*, *Salmonella typhimurium* and *Staphylococcus aureus* in ground beef with cranberry concentrate by thin agar layer method. *J of Rapid method and Automation in Microbiology*. 2007 Sep;15(3):282-94
- Raz R, Chazan B, Dan M. Cranberry juice and urinary tract infection. *Clinical Infectious Diseases*. 2004;38(May):1413-1419
- Sparkes AH. Feline Lower Urinary Tract Disease. *Proceedings of the 2006 World Congress WSAVA*. Praga:354-356
- Turner A, Chen SN, Joike MK, Pendland SL, Pauli GF, Farnsworth NR. Inhibition of uropathogenic *E. coli* by cranberry juice: a new antiadherence assay. *J Agric Food Chem*. 2005 Nov 16;53(23):8940-7
- Winn SG, Fougere BJ. *Veterinary Herbal Medicine*. 2007 *Mosby Elsevier*
- Yamanaka A, Kouchi T, Kasai K, Kato T, Ishihara K, Okuda K. Inhibitory effect of cranberry polyphenol on biofilm formation and cysteine proteases of *Porphyromonas gingivalis*. *J Periodontol Res*. 2007 Dec;42(6):589-92
- Yarnell E. Botanical medicines for the urinary tract. *World J Urol* (2002) 20:285-289
- Zafiri D, Ofek I, Adar R, Pocino M, Sharon N. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated *Escherichia coli* to eucaryotic cells. *Antimicrobial Agents and Chemotherapy*. 1989 Jan;33(1):92-98